Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia

BACKGROUND: Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib may be associated with underrecognized cardiotoxicities. CASE PRESENTATION: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Lisa, Fowler, Brian, Campbell, Courtney M., Slivnick, Jeremy, Nawaz, Haseeb, Kaka, Yaquta, Ruz, Patrick, Vallakati, Ajay, Baliga, Ragavendra, Vasu, Sumithira, Addison, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531894/
https://www.ncbi.nlm.nih.gov/pubmed/34686212
http://dx.doi.org/10.1186/s40959-021-00122-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531894/
https://www.ncbi.nlm.nih.gov/pubmed/34686212
http://dx.doi.org/10.1186/s40959-021-00122-x

Ejemplares similares